Ruxolitinib Is Under Investigation as JAK Inhibition Strategy for Multiple Myeloma
CancerNetwork® spoke with James R. Berenson, MD, founder, medical and scientific director, and president and chief...
IMBCR – KTLA 5 News – Segment 4
All Press
Make an Appointment
Related Articles
Ruxolitinib Elicits Few Adverse Effects When Treating Multiple Myeloma
CancerNetwork® spoke with James R. Berenson, MD, president and medical director of the Berenson Cancer Center, and...
Ruxolitinib/Selinexor Combo Is Being Evaluated for Multiple Myeloma
Encouraging preclinical data foreground a clinical trial evaluating ruxolitinib (Jakafi) with selinexor (Xpovio) in...